The pharmaceutical industry is using artificial intelligence to speed up drug discovery, with companies like Eli Lilly and Sanofi striking licensing deals with AI companies.
https://t.co/LmKo8sruON
Deep value investing, to me, is not about big discounts. It’s about finally seeing something profound and deep underneath the surface, when others are still only seeing the tip of the iceberg, and still making judgements.
A book — published in 2005 — predicted the COVID-19 pandemic, financial collapse, the war in Iran ... and nobody's talking about it.
https://t.co/U2y9kSgrK7
It's AI vs AI.
Optum (probably using AI) recently denied my doc's request for prior approval on an Rx he felt I needed.
I drafted an appeal letter with help from Claude.
My physician signed the letter & faxed it to Optum.
PA decision reversed. Rx approved.
AI vs AI.
When I was consulting for @HBO Silicon Valley, zero-loss compression was the holy grail Richard Hendricks chases that perfect middle-out algo could shrink everything w/out breaking a single bit.
Google just did something even more practical for the AI era: TurboQuant compresses LLM key-value caches down to 3 bits per value using random orthogonal rotation + PolarQuant scalar quantization & optional 1-bit QJL residual correction.
=>> 6× memory reduction, up to 8× faster attention (on H100), & 0 degradation on LongBench, Needle-in-a-Haystack, and RULER for models like Gemma. No retraining, no calibration needed.
Fiction just got out-engineered by reality. 😅💚💚
Hosting leaders and innovators in healthcare is what makes this podcast special. Today on #HealthcareUnfiltered, I host Katherine Stueland, CEO of @GeneDx to talk genomics for rare diseases & leadership.
@doctorpemm @VivekSubbiah
https://t.co/hS6uRfuLHh
Tom on #HealthcareUnfiltered, you're in for a treat as I host the President & CEO of @GeneDx Katherine Stueland who under her leadership, the company is making major strides in combatting "rare diseases' through genomics.
Wide range interview W many lessons learned. Pls tune in